ALDX — Aldeyra Therapeutics, Inc.

Summary of Aldeyra Therapeutics Q4 2022 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of December 31, 2022, Aldeyra had cash, cash equivalents, and marketable securities totaling $174.3 million, projected to fund operations into the second half of 2024.
• Net Loss: The net loss for 2022 was $62.0 million ($1.06 per share), compared to a net loss of $57.8 million ($1.07 per share) in 2021.
• Operating Expenses: Total operating expenses increased to $62.7 million from $56.2 million in 2021, driven by higher R&D and administrative costs.

2. Strategic Updates and Business Highlights

• FDA Applications: Aldeyra achieved significant milestones with two FDA accepted new drug applications (NDAs):
  • Reproxalap for dry eye disease, with a PDUFA date set for November 23, 2023.
  • ADX-2191 for primary vitreoretinal lymphoma, receiving priority review with a PDUFA date of June 21, 2023.
• Clinical Trials: The company is advancing its RASP modulation platform with multiple candidates (ADX-629, ADX-246, ADX-248) targeting various systemic and ocular diseases. Top-line results from several Phase 2 trials are expected in the second half of 2023.
• Commercialization Plans: Aldeyra is preparing for the potential commercialization of Reproxalap and ADX-2191, focusing on internal launch strategies while engaging in partnering discussions.

3. Forward Guidance and Outlook

• The company anticipates that its cash reserves will support initial commercialization efforts for both Reproxalap and ADX-2191 if approved.
• Aldeyra is optimistic about the potential of its RASP modulation platform and expects to validate its approach through ongoing and upcoming clinical trials.

4. Bad News, Challenges, or Points of Concern

• Net Losses: The continued net losses raise questions about the sustainability of operations without significant revenue generation.
• Regulatory Risks: While the acceptance of NDAs reduces some regulatory risks, the outcomes of the FDA reviews remain uncertain.
• Market Competition: The competitive landscape for dry eye treatments and retinal therapies may pose challenges, particularly if other companies advance similar products.

5. Notable Q&A Insights

• Side Effect Profile: Dr. Brady emphasized the favorable safety profile of ADX-629, noting no serious adverse events reported to date, which could differentiate it from existing therapies.
• Partnering Discussions: The company is actively engaging with multiple potential partners for Reproxalap, with expectations that partners will want to be involved before label negotiations.
• Commercial Strategies: The commercialization approach for Reproxalap will target optometrists, while ADX-2191 will focus on a limited number of retinal specialists, reflecting the different market dynamics for each product.
• Visual Acuity Data: The improvement in visual acuity observed in the Reproxalap safety trial was highlighted as a significant differentiator, with expectations that this data will be included in the NDA submission.

Overall, Aldeyra Therapeutics is positioned for a pivotal year in 2023, with several key regulatory milestones and clinical trial results on the horizon, despite ongoing financial losses and market competition challenges.